## In the claims:

- 1. (Currently amended) A An isolated, stable glutamic acid decarboxylase (GAD)-peptide-specific Class II  $\it MHC$  complex which comprises a recombinant peptide chain comprising (1) the extracellular portion of the  $\it \beta$  chain of a Class II  $\it MHC$  molecule selected from the group consisting of I-Ag7 and DQ, and (2) a GAD peptide selected from the group consisting of SEQ ID NOS:1-13.
- 2. (Previously presented) The complex of claim 1 wherein said complex further comprises the extracellular portion of the  $\alpha$  chain of said Class II *MHC* molecule.
- 3. (Previously presented) The complex of claim 1, wherein said Class II  $\emph{MHC}$   $\beta$  chain lacks a complete transmembrane region.
- 4. (Previously presented) The complex of claim 2, wherein said Class II MHC  $\beta$  chain and said Class II MHC  $\alpha$  chain lack complete transmembrane regions.

## 5-10. (Canceled).

- 11. (Previously presented) The complex of claim 1, wherein said GAD peptide is SEQ ID NO: 1.
- 12. (Previously presented) The complex of claim 1, wherein said GAD peptide is SEQ ID NO: 2.

- 13. (Previously presented) The complex of claim 1 which further comprises a biotinylation site.
- 14. (Previously presented) The complex of claim 1 which further comprises an oligohistidine sequence.
- 15. (Previously presented) The complex of claim 2 which further comprises a biotinylation site.
- 16. (Previously presented) The complex of claim 2 which further comprises an oligohistidine sequence.
- 17-22. (Canceled).
- 23. (Currently amended) A An isolated, stable glutamic acid decarboxylase (GAD)-peptide-specific Class II  $\it MHC$  complex which comprises (1) the extracellular portion of a  $\beta$  chain of a Class II  $\it MHC$  molecule selected from the group consisting of I-Ag7 and DQ, (2) the extracellular portion of an  $\alpha$  chain of said Class II  $\it MHC$  molecule, and (3) a GAD peptide selected from the group consisting of SEQ ID NOS:1-13.
- 24. (Previously presented) The complex of claim 23 which further comprises a biotinylation site.
- 25. (Previously presented) The complex of claim 23 which further comprises an oligohistidine sequence.
- 26-31. (Canceled).

- 32. (Previously presented) The complex of claim 24 which further comprises a biotin covalently linked to said biotinylation site.
- 33. (Previously presented) The complex of claim 32 which further comprises an effector-avidin bound to said biotin.
- 34. (Previously presented) The complex of claim 33, wherein said effector is selected from a label and a toxin.
- 35-52. (Canceled).
- 53. (Previously presented) The complex of claim 1 which is a tetrameric complex.
- 54. (Previously presented) The complex of claim 23 which is a tetrameric complex.